1
Feb
2022
Targeting Integrins With Small Molecules: Praveen Tipirneni on The Long Run
Today’s guest on The Long Run is Praveen Tipirneni. Praveen is the CEO of Waltham, Mass.-based Morphic Therapeutic. Morphic Therapeutic is developing oral small molecule drugs aimed at integrin targets. There’s some fascinating biology and computational technology underpinning this work, which I discussed a couple years ago on The Long Run with Morphic scientific founder Tim Springer. Just to review... Read More
31
Jan
2022
Gandeeva Raises $40m For Fast Cryo-EM Enabled Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jan
2022
A Small Step on Drug Pricing
Mark Cuban, the billionaire-turned-reality TV star, made news this week with the Mark Cuban Cost Plus Drug Company. Cuban has been saying for a while that he wants to stick it to the man. The biopharma man. “I could make a fortune from this,” Cuban told Texas Monthly in September. “But I won’t. I’ve got enough money. I’d rather f—... Read More
27
Jan
2022
Simcha, Backed by SR One, Raises $40m to Inject New Life Into IL-18 for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jan
2022
Reflecting on MLK and Science in Society
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jan
2022
ImmPACT Bio, with Bispecific CAR-T Showing Durable CRs, Raises $111m Series B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jan
2022
The Biogen Debacle Continues
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jan
2022
Antibody Engineering & Company Building: Bassil Dahiyat on The Long Run
Today’s guest on The Long Run is Bassil Dahiyat. Bassil is the CEO of Monrovia, Calif.-based Xencor. He’s been on a true Long Run. Bassil co-founded Xencor in 1997 after getting his PhD in chemistry at Caltech. He’s been through a lot of ups and downs in the biotech markets, and taken the company through a couple big strategic shifts.... Read More
6
Jan
2022
Biotech’s Candle Burns Bright in the Dark
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Dec
2021
Pfizer, Merck Get COVID Drugs OK’d, Sanofi Buys Amunix, and a New PCSK9 Contender
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Dec
2021
Physician-Scientist-Biotech VC: Vineeta Agarwala on The Long Run
Today’s guest on The Long Run is Vineeta Agarwala. Vineeta is a general partner with Andreesen Horowitz’s bio fund. Vineeta has spent a lot of time on the front lines of an explosion in biological data, and efforts to analyze it to develop better therapeutics, diagnostics and digital health applications. Before coming to A16Z, she worked at GV and Flatiron... Read More
16
Dec
2021
JPM Goes Virtual, Pfizer Acquires Arena, & Arc Reimagines the Scientific Enterprise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Dec
2021
A Missed Opportunity for Grownups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Dec
2021
Newpath Partners Secures $350M for Startups Working on Hard Science Problems
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Dec
2021
Targeted Small Molecule Protein Degraders: Nello Mainolfi on The Long Run
Today’s guest on The Long Run is Nello Mainolfi. Nello is the president and CEO of Cambridge, Mass.-based Kymera Therapeutics. Kymera is working on targeted protein degraders. These are orally available small molecule compounds. Many in biopharma are excited about them because they have a clever design that allows them to go after targets that have previously been out of... Read More
2
Dec
2021
The Variant on the Move
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Dec
2021
T Cell Therapies for Autoimmunity: Jeff Bluestone on The Long Run
Today’s guest on The Long Run is Jeff Bluestone. Jeff is the president and CEO of South San Francisco-based Sonoma Biotherapeutics. Jeff has a long, distinguished history as an immunology researcher at the University of Chicago and UCSF. He learned over the years how to enlarge his impact by coordinating groups of scientists as an administrator at the Immune Tolerance... Read More
1
Dec
2021
Apollo Health Ventures Gets $180M to Invest in Extending Human Healthspan
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Nov
2021
Reviving Targeted Radiopharmaceuticals for Cancer: Ken Song on The Long Run
Today’s guest on The Long Run is Ken Song. Ken is the CEO of San Diego-based RayzeBio. At RayzeBio, Ken discovered new opportunity in an area cancer R&D that had been long ago abandoned. It’s about creating targeted cancer therapies loaded with radioactive isotopes to give them extra tumor-killing punch. These aren’t the same thing as antibody-drug conjugates, in which... Read More
18
Nov
2021
Califf Gets FDA Nod, Novo Acquires Dicerna, & a Shrewd Investment in Pittsburgh
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.